---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-122839"
form_type: "8-K"
ticker: "CRBP"
cik: "0001595097"
company_name: "Corbus Pharmaceuticals Holdings, Inc."
filed_at: "2024-11-07T23:59:59+00:00"
generated_at: "2026-05-30T03:34:11.024065+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Corbus Q3 net loss $13.8M; CRB-701 dose escalation complete; cash $159.4M

## Summary
- Net loss of $13.8M ($1.15/diluted share) vs $10.1M ($2.27) in Q3 2023; operating expenses up $6.0M to $15.5M.
- Cash, cash equivalents and investments $159.4M; expects to fund operations through Q3 2027.
- Raised $35.6M net proceeds via ATM program in Q3 by issuing 663,730 shares.
- Completed enrollment in CRB-701 dose escalation part of Phase 1; first data expected in Q1 2025.
- Final $11.8M loan payment made; loan fully paid off.

## SEC filing metadata
- accession: 0000950170-24-122839
- form_type: 8-K
- ticker: CRBP
- cik: 0001595097
- company_name: Corbus Pharmaceuticals Holdings, Inc.
- filed_at: 2024-11-07T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1595097/000095017024122839/0000950170-24-122839-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1595097/000095017024122839/crbp-20241107.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-122839
- JSON: https://secwatch.observer/filing/0000950170-24-122839.json
- Plain text: https://secwatch.observer/filing/0000950170-24-122839.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.